Evaluation of the clinical efficacy of adding metformin to chemotherapy regimen for patients with ovarian cancers

Trial ID #	IRCT2016- 022726788N1
Phase	II
Drug Class	Signaling Pathway Inhibitors: PI3K-AKT-mTOR/mTOR
Drug Name	Metformin
Alternate Drug Names	Fortamet, Glucophage, Glumetza, Riomet
Drugs in Trial	Carboplatin, Metformin, Paclitaxel
Eligible Participant	Newly diagnosed stage I-III ovarian cancer
Patients Enrolled	70
Therapy Setting	First-line
Study Design	Open-Label, Randomized
Endpoints	RFS, evaluated per CA125
Efficacy	CarboPt+Pac+Met (n=30) vs CarboPt+Pac (n=40): RFS: 48.0 vs 25.7 months 4-year rate of recurrence: 67.5 vs 13.3%
Clinically Significant Adverse Events	CarboPt+Pac+Met vs CarboPt+Pac: Grade 1-4 AE: abdominal discomfort (20 vs 0%)
Conclusion	Improved RFS with addition of metformin to carboplatin+paclitaxel in stage I-III patients
Reference	Hamedi B et al. Combination of Metformin and Chemotherapy Decreases the Recurrence Rates of Epithelial Ovarian Cancers: A Randomized Clinical Trial. Int J Cancer Manag (2018) 11(7): e11621 https://brieflands.com/articles/ijcm-11621